Matches in SemOpenAlex for { <https://semopenalex.org/work/W2344707946> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2344707946 endingPage "S95" @default.
- W2344707946 startingPage "S95" @default.
- W2344707946 abstract "Psoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation and inflammation, leading to disrupted skin barrier function. The use of natural agents that possess the ability to abrogate these effects could be useful for the treatment of psoriasis. Earlier studies have shown that treatment of keratinocytes and mouse skin with the green tea polyphenol, epigallocatechin-3-gallate (EGCG), increased the expression of caspase-14 that is involved in epidermal differentiation and cornification. However, dose and bioavailability restrict the therapeutic development and application of EGCG in the treatment of psoriasis. To overcome these limitations, we developed fully characterized, chitosan-based nanocarrier to encapsulate EGCG (hereafter termed as nanoEGCG) suitable for topical delivery. Here, we assessed the efficacy of nanoEGCG (48mg/animal) using an IMQ-induced mouse psoriasis-like skin model and compared the effects to free EGCG (1mg/amimal). Treatment with nanoEGCG resulted in significant (p<0.01) amelioration of pathological markers of psoriasiform lesions including reduction in i) ear and skin thickness, erytherma and scales, ii) proliferation (Ki-67), iii) infiltratory immune cells (mast cells, neutrophils, macrophages and CD4+ T cells), iv) angiogenesis (CD31), and v) increase in the protein expression of caspase-14, early (K1 and k10) and late (filaggrin and loricrin) differentiation markers and AP-1 factors (JunB and cJun), and (v) modulates several psoriasis-related inflammatory cytokines and chemokines analyzed compared to high dose of free EGCG (p<0.05). Taken together, topical application of nanoEGCG was found to ameliorate IMQ-induced Balb/c mouse psoriasis-like lesions with greater than 25-fold dose advantage over free EGCG. Our observations warrant further in vivo efficacy studies of this unique nanoEGCG formulation in robust inducible and genetic models of psoriasis." @default.
- W2344707946 created "2016-06-24" @default.
- W2344707946 creator A5016637177 @default.
- W2344707946 creator A5018742494 @default.
- W2344707946 creator A5020733118 @default.
- W2344707946 creator A5051459543 @default.
- W2344707946 creator A5056493503 @default.
- W2344707946 creator A5069063034 @default.
- W2344707946 creator A5070873484 @default.
- W2344707946 creator A5082425428 @default.
- W2344707946 date "2016-05-01" @default.
- W2344707946 modified "2023-10-05" @default.
- W2344707946 title "537 Topical application of chitosan-based nanoformulated green tea polyphenol EGCG ameliorates imiquimod-induced psoriasis-like skin lesion in mice" @default.
- W2344707946 doi "https://doi.org/10.1016/j.jid.2016.02.575" @default.
- W2344707946 hasPublicationYear "2016" @default.
- W2344707946 type Work @default.
- W2344707946 sameAs 2344707946 @default.
- W2344707946 citedByCount "0" @default.
- W2344707946 crossrefType "journal-article" @default.
- W2344707946 hasAuthorship W2344707946A5016637177 @default.
- W2344707946 hasAuthorship W2344707946A5018742494 @default.
- W2344707946 hasAuthorship W2344707946A5020733118 @default.
- W2344707946 hasAuthorship W2344707946A5051459543 @default.
- W2344707946 hasAuthorship W2344707946A5056493503 @default.
- W2344707946 hasAuthorship W2344707946A5069063034 @default.
- W2344707946 hasAuthorship W2344707946A5070873484 @default.
- W2344707946 hasAuthorship W2344707946A5082425428 @default.
- W2344707946 hasBestOaLocation W23447079461 @default.
- W2344707946 hasConcept C190684412 @default.
- W2344707946 hasConcept C203014093 @default.
- W2344707946 hasConcept C2776914184 @default.
- W2344707946 hasConcept C2778329239 @default.
- W2344707946 hasConcept C2779112978 @default.
- W2344707946 hasConcept C2780564577 @default.
- W2344707946 hasConcept C502942594 @default.
- W2344707946 hasConcept C71924100 @default.
- W2344707946 hasConcept C8891405 @default.
- W2344707946 hasConcept C98274493 @default.
- W2344707946 hasConceptScore W2344707946C190684412 @default.
- W2344707946 hasConceptScore W2344707946C203014093 @default.
- W2344707946 hasConceptScore W2344707946C2776914184 @default.
- W2344707946 hasConceptScore W2344707946C2778329239 @default.
- W2344707946 hasConceptScore W2344707946C2779112978 @default.
- W2344707946 hasConceptScore W2344707946C2780564577 @default.
- W2344707946 hasConceptScore W2344707946C502942594 @default.
- W2344707946 hasConceptScore W2344707946C71924100 @default.
- W2344707946 hasConceptScore W2344707946C8891405 @default.
- W2344707946 hasConceptScore W2344707946C98274493 @default.
- W2344707946 hasIssue "5" @default.
- W2344707946 hasLocation W23447079461 @default.
- W2344707946 hasOpenAccess W2344707946 @default.
- W2344707946 hasPrimaryLocation W23447079461 @default.
- W2344707946 hasRelatedWork W12437156 @default.
- W2344707946 hasRelatedWork W1987285458 @default.
- W2344707946 hasRelatedWork W2026070802 @default.
- W2344707946 hasRelatedWork W2068440684 @default.
- W2344707946 hasRelatedWork W2126356325 @default.
- W2344707946 hasRelatedWork W2295017376 @default.
- W2344707946 hasRelatedWork W2793159610 @default.
- W2344707946 hasRelatedWork W2914996562 @default.
- W2344707946 hasRelatedWork W3084617491 @default.
- W2344707946 hasRelatedWork W3152882536 @default.
- W2344707946 hasVolume "136" @default.
- W2344707946 isParatext "false" @default.
- W2344707946 isRetracted "false" @default.
- W2344707946 magId "2344707946" @default.
- W2344707946 workType "article" @default.